News Releases

Loxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

INDIANAPOLIS, Oct. 4, 2023 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that preclinical data for agents targeting KRAS G12D, multiple oncogenic KRAS mutations and Nectin-4, will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023, in Boston. These programs are among the next slate of new oncology agents planned to enter clinical trials for Loxo@Lilly in 2024.

The poster presentations will include preclinical characterization data for a highly potent inhibitor of KRAS G12D that is selective against wild-type KRAS, a highly potent and isoform-selective pan-KRAS inhibitor with activity against a broad spectrum of the most common activating KRAS mutations and high selectivity over wild-type HRAS and NRAS, and a fully human monoclonal anti-Nectin-4 antibody conjugated to a topoisomerase I (TOPO 1) inhibitor.

"This marks the first preclinical data for three of the new molecules planned to enter clinical trials next year in areas of cancer biology with continued need for new and better treatment options," said Jacob Van Naarden, president, Loxo@Lilly. "These new programs represent years of focused work to create differentiated molecules against exacting target product profiles. We look forward to moving these programs into the clinic over the next year."

Details on poster presentations are below:

Presentation Title: Preclinical characterization of LY3962673, an orally bioavailable, highly potent, and selective KRAS G12D inhibitor
Abstract Number: B115
Presentation Date & Time: Friday October 13, 12:30pm4:00pm ET
Session: Poster Session B
Presenter: Chandrasekar Iyer

Presentation Title: Preclinical characterization of orally bioavailable, highly potent pan-KRAS inhibitors with selectivity over HRAS and NRAS
Abstract Number: B116
Presentation Date & Time: Friday October 13, 12:30pm4:00pm ET
Session: Poster Session B
Presenter: Lourdes Prieto Vallejo

Presentation Title: Preclinical characterization of ETx-22, a next-generation antibody drug conjugate (ADC) targeting Nectin-4
Abstract Number: B128
Presentation Date & Time: Friday October 13, 12:30pm4:00pm ET
Session: Poster Session B
Presenter: Joanna Fares

About Lilly
Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on FacebookInstagramTwitter and LinkedIn. P-LLY

Lilly Forward-Looking Statement
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Lilly's oncology pipeline, including therapies under development, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there can be no guarantee that studies will be initiated or completed as planned, that future study results will be consistent with the results to date, or that any of these therapies will receive initial regulatory approvals or approvals for additional indications, as applicable, or be commercially successful. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.


Refer to:

Megan Talon;; 463-209-1470 (Media)
Joe Fletcher;; 317-296-2884 (Investors)


(PRNewsfoto/Eli Lilly and Company)


SOURCE Eli Lilly and Company